Volume 19 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(9): 1477-1479,1496
LIU Jin-feng, WANG Zhang-gui, CUI Zhen. Efficacy analysis of albumin paclitaxel and radiotherapy in locally advanced oesophageal cancer[J]. Chinese Journal of General Practice, 2021, 19(9): 1477-1479,1496. doi: 10.16766/j.cnki.issn.1674-4152.002090
Citation: LIU Jin-feng, WANG Zhang-gui, CUI Zhen. Efficacy analysis of albumin paclitaxel and radiotherapy in locally advanced oesophageal cancer[J]. Chinese Journal of General Practice, 2021, 19(9): 1477-1479,1496. doi: 10.16766/j.cnki.issn.1674-4152.002090
shu

Efficacy analysis of albumin paclitaxel and radiotherapy in locally advanced oesophageal cancer

doi: 10.16766/j.cnki.issn.1674-4152.002090
  • 1.

    Department of Radiation Therapy, the Second People's Hospital of Anhui Province, Hefei, Anhui 230041, China

Funds:

 KJ2019A0357

  • Received Date: 2020-11-21
    Available Online: 2022-02-15
    Abstract
  •   Objective  Synchronous radiotherapy and chemotherapy is the first choice for inoperable treatment of locally advanced oesophageal cancer. Taxane chemotherapy drugs combined with cisplatin and concurrent radiotherapy and chemotherapy have been widely used in clinical practice. Therefore, the purpose of this study is to observe the safety and clinical efficacy of albumin paclitaxel combined with cisplatin and concurrent radiotherapy and chemotherapy in locally advanced oesophageal cancer.   Methods  Retrospective analysis was performed on a total of 45 patients with locally advanced esophageal cancer admitted to the Department of Radiotherapy of the Second People's Hospital of Anhui Province from January 2018 to July 2019. All received radical concurrent radiotherapy and chemotherapy, Among them, 22 patients received concurrent chemotherapy with albumin paclitaxel and cisplatin (experimental group) and 23 patients received concurrent chemoradiotherapy with cisplatin (control group), Three months after the end of concurrent radiotherapy and chemotherapy, chest CT, barium meal and other examinations were performed to evaluate the clinical efficacy, and the patients were followed up by telephone for a 1-year disease-free survival rate.   Results  The objective response rate (ORR) of the albumin paclitaxel+cisplatin concurrent radiotherapy and chemotherapy group was 77.3%, and the ORR of the cisplatin concurrent radiotherapy and chemotherapy group was 47.8%. The difference between the two groups was not statistically significant (P < 0.05). The overall survival rate (90.2%) of the albumin paclitaxel+cisplatin concurrent radiotherapy and chemotherapy group was higher than that of the cisplatin concurrent radiotherapy group (78.0%). A statistically significant difference was observed in peripheral nerve injury (P < 0.05), but most of them were grade 1 to 2 reactions, which could be tolerated by patients.   Conclusion  The clinical effect of albumin paclitaxel combined with cisplatin concurrent radiotherapy and chemotherapy on locally advanced oesophageal cancer is good, the 1-year survival rate is high, and the adverse reactions are tolerable.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    CHEN W, ZHENG R, BAADE P D, et al. Cancerstatistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
    [2]
    戴婷婷, 王万伟, 仝宇梭, 等. 多西他赛联合顺铂同步放化疗和单纯放疗治疗老年非手术食管鳞癌的临床疗效分析[J]. 实用癌症杂志, 2019, 34(3): 417-420. doi: 10.3969/j.issn.1001-5930.2019.03.019
    [3]
    TU C C, HSU P K. The frontline of esophageal cancer treatment: Questions to be asked and answered[J]. Ann Transl Med, 2018, 6(4): 83. doi: 10.21037/atm.2017.10.31
    [4]
    林展, 梁雷锋, 覃金莲, 等. 局部晚期食管癌根治性同步放化疗放疗剂量60 Gy对比50.4 Gy的临床研究[J]. 名医, 2020(4): 85. https://www.cnki.com.cn/Article/CJFDTOTAL-MGYI202004077.htm
    [5]
    COOPER J S, GUO M D, HERSKOVIC A, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)[J]. JAMA, 1999, 281(17): 1623-1627. http://europepmc.org/abstract/med/10235156
    [6]
    JING W, YAN W W, LIU Y G, et al. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma[J]. Cancer Biol Thera, 2019, 20(5): 1121-1126. http://www.onacademic.com/detail/journal_1000042291111099_71a9.html
    [7]
    SUNTHARALINGAM M, WINTER K, ILSON D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG oncology RTOG0436 phase 3 randomized clinical trial[J]. JAMA Oncology, 2017, 3(11): 1520-1528. doi: 10.1001/jamaoncol.2017.1598
    [8]
    CHEN Y, YE J, ZHU Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy forlocally advanced esophageal squamous cell cancer: A randomized, multicenter, phase Ⅲ clinical trial[J]. J Clin Oncol, 2019, 37(20): 1695-1703. doi: 10.1200/JCO.18.02122
    [9]
    DAS M, SAIKIA B J, SHARMA S K, et al. p16 hypermethylation: A biomarker for increased esophageal cancer susceptibility in high incidence region of North East India[J]. Tumor Biology, 2015, 36(3): 1627-1642. doi: 10.1007/s13277-014-2762-7
    [10]
    JOHN T A, VOGEL S M, TIRUPPATHI C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelia lmonolayer[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 284(1): L187-196. doi: 10.1152/ajplung.00152.2002
    [11]
    范丽萍, 焦园园, 郭子寒, 等. 白蛋白结合型紫杉醇与溶剂型紫杉醇治疗转移性乳腺癌的最小成本分析[J]. 中国药房, 2016, 27(32): 4477-4479. doi: 10.6039/j.issn.1001-0408.2016.32.04
    [12]
    张惠茹. 白蛋白结合型紫杉醇治疗晚期乳腺癌的疗效及安全性[J]. 中国实用医药, 2016, 11(23): 166-167. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201623118.htm
    [13]
    张德智, 王璐瑶, 梁怀虹. 中晚期食管癌患者3D-CRT同步化疗的临床效果[J]. 中国实用医药, 2017, 12(3): 25-27. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201703011.htm
    [14]
    张定富, 吴秋芳, 戈长征, 等. 顺铂联合5-FU化疗同步放疗治疗食管癌的临床效果[J]. 现代肿瘤医学, 2017, 25(13): 2061-2064. doi: 10.3969/j.issn.1672-4992.2017.13.013
    [15]
    戚诚, 赵晓东, 刘博, 等. 华蟾素胶囊联合同步放化疗治疗局部晚期食管癌的疗效分析[J]. 中国肿瘤临床与康复, 2017, 24(5): 525-528. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201705004.htm
    [16]
    范俊利, 雷彩鹏, 张卫国. 多烯紫杉醇联合奈达铂同步放化疗治疗局部中晚期食管癌疗效观察[J]. 哈尔滨医药, 2019, 39(6): 523-524. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYY201906011.htm
    [17]
    SONG T, ZHANG X B, FANG M, et al. Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: A prospective phase Ⅱ trial[J]. Cancer Med, 2016, 5(12): 3371-3377. doi: 10.1002/cam4.897
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (210) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return